|Over a week ago|
Codex DNA announces licensing, supply deal with TriLink for CleanCap » 07:1807/2107/21/21
Codex DNA (DNAY)…
Codex DNA (DNAY) announced a licensing and supply agreement with TriLink Biotechnologies, part of Maravai LifeSciences (MRVI), for its CleanCap technology. Codex DNA will integrate the mRNA capping technology into its suite of automated mRNA synthesis kits for the BioXp system as well as within the company's BioFoundry Services offering. "Together, the technologies are expected to increase productivity and yields for mRNA synthesis workflows, potentially opening the doors for a broader range of downstream therapeutic and vaccine applications," the company said.
Cowen starts 'promising' Codex DNA at Outperform » 08:5507/1307/13/21
As previously reported,…
As previously reported, Cowen analyst Doug Schenkel initiated coverage of Codex DNA with an Outperform rating and no price target. Codex DNA's commercial-stage BioXp platform offers a replacement for existing DNA "in house" build workflows that are often "unreliable, inefficient, and largely manual," said Schenkel. The "promising entrant in synthetic DNA assembly" has a vision for an onsite end-to-end solution across the full continuum of DNA synthesis, DNA build, DNA scale-up, RNA synthesis and modification, and protein synthesis and modification, Schenkel added. He expects investor confidence to be "fortified" if Codex DNA continues to have continued commercial success, Schenkel added.
Jefferies starts 'discounted' Codex DNA at Buy with $23 price target » 07:2107/1307/13/21
As previously reported,…
As previously reported, Jefferies analyst Brandon Couillard initiated coverage of Codex DNA with a Buy rating and $23 price target. Codex already has a strong installed base of greater than 160 systems that he thinks could grow to over 1,200 units by 2025, said Couillard, who adds that the stock currently trades at a "discount to peers" based on his FY23 revenue estimates.
Codex DNA initiated with a Buy at Jefferies » 06:2607/1307/13/21
Jefferies analyst Brandon…
Jefferies analyst Brandon Couillard initiated coverage of Codex DNA with a Buy rating and $23 price target.
Codex DNA initiated with an Outperform at Cowen » 06:2607/1307/13/21
Cowen analyst Doug…
Cowen analyst Doug Schenkel initiated coverage of Codex DNA with an Outperform rating.
Codex DNA initiated with an Overweight at KeyBanc » 06:2207/1307/13/21
KeyBanc analyst Paul…
KeyBanc analyst Paul Knight initiated coverage of Codex DNA with an Overweight rating and $30 price target. The analyst Codex as a "transformative" technology provider in the synthetic biology market with the only end-to-end automation platform for rapid synthesis of biologically active DNA, mRNA, and proteins. He estimates the company grows revenue approximately 100% per year with potential upside.
Opening Day: Moving iMage moves up on market debut » 08:1207/1007/10/21
SNTG, RNAZ, AGRI, MITQ, LDOC, DIDI, BABA, CYT, FEMY, DNAY, AMAM, TRMR, ATAI, IPSC, VERV, LYEL, ISPC, HOOD, RGCB, QNIU, CMSL, SPRK, BLND, SCAN, VTEX, GAMB, DUOL, AUTH, RXST
Shares of Moving iMage…
|Over a month ago|
Codex DNA Inc trading resumes 15:1106/3006/30/21
Codex DNA Inc trading halted, volatility trading pause 15:0606/3006/30/21
Opening Day: WalkMe stock price falls following $287M IPO » 08:3406/1906/19/21
CYT, FEMY, AMAM, DNAY, TRMR, ATAI, IPSC, RERE, VERV, LYEL, ISPC, WKME, MOLN, CNVY, ALZN, FLYW, PAY, ZIP, DAWN, FIGS, OMIC, CNTA, DIDI, QNIU, RGCB, ELEV, CMSL, DNUT, YOU, GS, MS, JPM, AMZN, F, SAFO, HOOD
Backed by Insight Venture…